Scarica l'app Stockscreener
18.57
2.88%
0.52
Pre-mercato:
18.77
0.20
+1.08%
Precedente Chiudi:
$18.05
Aprire:
$18.26
Volume 24 ore:
505.96K
Relative Volume:
0.65
Capitalizzazione di mercato:
$1.28B
Reddito:
$161.10M
Utile/perdita netta:
$-308.60M
Rapporto P/E:
-3.9764
EPS:
-4.67
Flusso di cassa netto:
$-259.90M
1 W Prestazione:
+7.84%
1M Prestazione:
+0.49%
6M Prestazione:
-34.89%
1 anno Prestazione:
-49.01%
Intervallo 1D:
$17.66
$18.84
Intervallo di 1 settimana:
$17.35
$18.84
Portata 52W:
$17.08
$53.08
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Confronta ARVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
18.57 | 1.28B | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Assenagon Asset Management S.A. Buys 777 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire
Arvinas Repeat Insider Selling Not A Positive Indicator - Simply Wall St
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 - The Motley Fool
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains? - MSN
Arvinas (NASDAQ:ARVN) Sets New 12-Month LowShould You Sell? - MarketBeat
Arvinas stock touches 52-week low at $17.35 amid market challenges - Investing.com Australia
Arvinas outlines 2025 clinical trial plans for breast cancer drug By Investing.com - Investing.com Australia
Arvinas Announces Updates on Clinical Trials Progress - TipRanks
Arvinas outlines 2025 clinical trial plans for breast cancer drug - Investing.com India
Arvinas Updates Guidance for First- and Second-Line Phase 3 - GlobeNewswire
Arvinas Plans Two Phase 3 Trials for Breakthrough Breast Cancer Drug, Expands Pipeline for 2025 - StockTitan
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update - Business Upturn
Metastatic Prostate Cancer Market to Expand Significantly by 2034, States DelveInsight Report | Merck, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion Corporation - Barchart
Metastatic Prostate Cancer Market to Expand Significantly - openPR
JPMorgan Chase & Co. Grows Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
JPMorgan Chase & Co. Increases Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas (NASDAQ:ARVN) Trading 9.2% HigherHere's Why - MarketBeat
How To Trade (ARVN) - Stock Traders Daily
March 21st Options Now Available For Arvinas (ARVN) - Nasdaq
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Increases By 6.5% - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Sees Significant Increase in Short Interest - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Receives $63.50 Consensus Target Price from Brokerages - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Arvinas (NASDAQ:ARVN) Shares Down 3.3%Should You Sell? - MarketBeat
Arvinas' Vepdegestrant: Why The Data May Not Hold Up (NASDAQ:ARVN) - Seeking Alpha
Barclays PLC Purchases 80,984 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Long Term Trading Analysis for (ARVN) - Stock Traders Daily
Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by State Street Corp - MarketBeat
Arvinas (NASDAQ:ARVN) Trading Down 6.2%Time to Sell? - MarketBeat
New Haven-based Arvinas to expand Science Park footprint; renews leases - Hartford Business Journal
New Haven-based Arvinas to expand Science Park footprint; extends leases - Hartford Business Journal
Arvinas's SWOT analysis: biotech firm's stock faces pivotal trial results By Investing.com - Investing.com Australia
Arvinas's SWOT analysis: biotech firm's stock faces pivotal trial results - Investing.com
Metastatic Prostate Cancer Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Merck Sharp, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis - Barchart
Arvinas secures expanded New Haven premises until 2029 By Investing.com - Investing.com South Africa
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Increases By 5.6% - MarketBeat
Arvinas stock touches 52-week low at $21.17 amid market challenges - Investing.com Canada
(ARVN) Trading Advice - Stock Traders Daily
Arvinas's SWOT analysis: protein degrader's stock faces pivotal trial By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Lowers Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Holdings Lowered by BNP Paribas Financial Markets - Defense World
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):